Better cancer treatment

A trial of the PROphet blood test from Israel’s OncoHost (see here previously) has proved its accuracy and reliability in predicting the best treatment for metastatic non-small cell lung cancer (NSCLC) patients. OncoHost has received orders from 29 US cancer centers since its 2023 launch.–biomedical-analysis-publishes-study-analytically-validating-oncohosts-prophet-test-as-a-decision-support-tool-for-metastatic-nsclc-patients-301964509.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *